DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Phase 1

Recruiting

Conditions: Advanced Lung Carcinoma

Interventions: Drug: LK101 injection (personlized neoantigen pulsed DC vaccine )
Drug: Durvalumab
Drug: Pembrolizumab

First Posted Date: 2023-06-02

Last Posted Date: 2023-06-02

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT05886439

Locations: 🇨🇳
Cancer hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer
MSS

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05815303

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

Phase 2

Recruiting

Conditions: dMMR Colorectal Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05815290

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

MSLN-targeted CAR-T Cells in Solid Tumors.

Phase 1

Not yet recruiting

Conditions: Mesothelin-positive Advanced Malignant Solid Tumors

Interventions: Biological: Anti-mesothelin CAR-T cells

First Posted Date: 2023-03-24

Last Posted Date: 2023-03-24

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 87

Registration Number: NCT05783089

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Combination Product: anti-PD-1 or PD-L1 antibody
Radiation: postoperative radiaotherapy

First Posted Date: 2023-03-21

Last Posted Date: 2023-10-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 84

Registration Number: NCT05777824

Locations: 🇨🇳
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijin, Beijing, China

To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2

Recruiting

Conditions: COVID-19 Vaccine
COVID-19 Infection

Interventions: Other: no intervention

First Posted Date: 2023-03-17

Last Posted Date: 2023-03-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 700

Registration Number: NCT05774171

Locations: 🇨🇳
Sanhuan Cancer Hospital, Chaoyang District, Beijing(Cancer Hospital, Chinese Academy of Medical Sciences, close medical alliance), Beijing, Beijing, China

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Phase 2

Recruiting

Conditions: Breast Cancer
Radiotherapy Side Effect

Interventions: Radiation: Ultra-fractionated radiation therapy

First Posted Date: 2023-03-10

Last Posted Date: 2023-03-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 65

Registration Number: NCT05762900

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Phase 2

Recruiting

Conditions: Malignancy

Interventions: Drug: Al18F-PSMA-BCH PET/CT

First Posted Date: 2023-03-09

Last Posted Date: 2024-12-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 400

Registration Number: NCT05761366

Locations: 🇨🇳
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chaoyang, China

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

Phase 2

Recruiting

Conditions: Malignancy

Interventions: Drug: Al18F-NOTA-FAPI

First Posted Date: 2023-03-01

Last Posted Date: 2024-03-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT05749302

Locations: 🇨🇳
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chao Yang, China

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Breast Cancer
Chemotherapy Effect

Interventions: Drug: inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT05749016

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy